Synthorx Quick Ratio (THOR) starting from the third quarter 2019 to third quarter 2015, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Synthorx, Inc.  (NASDAQ: THOR)

Synthorx's Quick Ratio

THOR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2019, Quick Ratio fell to 18.06 above Synthorx, Inc. average.

Within Major Pharmaceutical Preparations industry 43 other companies have achieved higher Quick Ratio than Synthorx in third quarter 2019. While Quick Ratio total ranking in the third quarter 2019 has deteriorated compared to the prior quarter from 147 to 175.

Explain Quick Ratio?
How much Cash & cash equivalents THOR´s has?
What are THOR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

THOR Quick Ratio (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1		 (Dec 31 2018)
Q3		 (Jul 04 2015)
Q2
Y / Y Current Liabilities Change -89.96 % -89.18 % -89.99 % -92.01 % 20.25 %
Y / Y Cash & cash equivalent Change -44.93 % -31.28 % -22.19 % -24.22 % -5.92 %
Quick Ratio MRQ 18.06 22.29 21.99 26.75 3.29
THOR's Total Ranking # 175 # 147 # 135 # #
Seq. Current Liabilities Change 12.8 % -9.15 % 15.81 % -91.54 % 21.59 %
Seq. Cash & cash equivalent Change -8.65 % -7.9 % -4.79 % -31.25 % 13.98 %



Quick Ratio third quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 44
Healthcare Sector # 59
Overall Market # 175


Quick Ratio Statistics
High Average Low
22.29 7.13 2.82
(Jun 30 2019)   (Sep 27 2014)




Financial Statements
Synthorx's Current Liabilities $ 8 Millions Visit THOR's Balance sheet
Synthorx's Cash & cash equivalent $ 151 Millions Visit THOR's Balance sheet
Source of THOR's Sales Visit THOR's Sales by Geography


Cumulative Synthorx's Quick Ratio

THOR's Quick Ratio for the trailling 12 Months

THOR Quick Ratio

 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months		 (Dec 31 2018)
12 Months		 (Jul 04 2015)
12 Months
Y / Y Current Liabilities TTM Growth -90.37 % -65.55 % -46.48 % -21.16 % 11.59 %
Y / Y Cash & cash equivalent TTM Growth -31.17 % -20.16 % -17.21 % -18.2 % -15.17 %
Quick Ratio TTM 22.08 7.62 5.28 3.88 3.09
Total Ranking TTM # 4039 # 4217 # 4330 # #
Seq. Current Liabilities TTM Growth -70.75 % -36.58 % -30.52 % -25.24 % 4.56 %
Seq. Cash & cash equivalent TTM Growth -15.25 % -8.53 % -5.48 % -6.06 % -1.71 %

Quick ratio ranking by company, industry and sector >> Back to THOR Financial Strength Comparisons >> Go to Compare THOR Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Synthorx's average Cash & cash equivalent, this led to increase in in Synthorx's Quick Ratio to 22.08, above THOR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 448 other companies have achieved higher Quick Ratio than Synthorx. While Quick Ratio overall ranking has improved so far to 4039, from total ranking during the twelve months ending second quarter 2019 at 4217.

Explain Quick Ratio?
How much Cash & cash equivalents THOR´s has?
What are THOR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 449
Healthcare Sector # 844
Within the Market # 4039


trailing twelve months Quick Ratio Statistics
High Average Low
7.18 4.1 1.7
(Sep 30 2019)   (Mar 31 2012)




Companies with similar Quick Ratio in the quarter ending Sep 30 2019, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2019 MRQ Cash & cash equivalentSep 30 2019 MRQ Current Liabilities
Viking Therapeutics Inc   48.85 $ 288.072  Millions$ 5.897  Millions
Arena Pharmaceuticals Inc   45.36 $ 783.755  Millions$ 17.280  Millions
Lftd Partners Inc   41.83 $ 4.359  Millions$ 0.104  Millions
Allakos Inc   41.37 $ 517.004  Millions$ 12.498  Millions
Igm Biosciences Inc   37.68 $ 242.075  Millions$ 6.424  Millions
Karuna Therapeutics Inc   36.66 $ 54.144  Millions$ 1.477  Millions
Hookipa Pharma inc   35.46 $ 123.690  Millions$ 3.488  Millions
Infinity Pharmaceuticals Inc   34.54 $ 51.989  Millions$ 1.505  Millions
Gossamer Bio Inc   31.90 $ 446.472  Millions$ 13.998  Millions
Ligand Pharmaceuticals Incorporated  30.81 $ 1,099.685  Millions$ 35.695  Millions
Madrigal Pharmaceuticals Inc   29.93 $ 453.610  Millions$ 15.154  Millions
Nextcure Inc   28.73 $ 184.082  Millions$ 6.408  Millions
Aurinia Pharmaceuticals Inc   27.09 $ 306.019  Millions$ 11.295  Millions
Atreca inc   26.66 $ 201.038  Millions$ 7.540  Millions
Neurogene Inc   25.85 $ 66.306  Millions$ 2.565  Millions
Ra Pharmaceuticals Inc   25.08 $ 292.602  Millions$ 11.666  Millions
Uniqure N v   24.46 $ 403.163  Millions$ 16.484  Millions
Bridgebio Pharma Inc   23.68 $ 536.053  Millions$ 22.639  Millions
Ideaya Biosciences Inc   22.64 $ 109.356  Millions$ 4.831  Millions
Phasebio Pharmaceuticals Inc.  22.41 $ 81.771  Millions$ 3.649  Millions
Fulcrum Therapeutics Inc   20.31 $ 101.597  Millions$ 5.002  Millions
Satsuma Pharmaceuticals Inc   20.03 $ 118.948  Millions$ 5.938  Millions
Cryoport inc   19.99 $ 93.909  Millions$ 4.698  Millions
Xbiotech Inc   19.96 $ 40.338  Millions$ 2.021  Millions
Filana Therapeutics Inc   19.63 $ 17.804  Millions$ 0.907  Millions
Applied Therapeutics Inc   19.52 $ 32.954  Millions$ 1.688  Millions
Kura Oncology Inc   19.44 $ 250.126  Millions$ 12.865  Millions
Provention Bio Inc   19.17 $ 95.088  Millions$ 4.960  Millions
Seres Therapeutics Inc   18.81 $ 83.788  Millions$ 4.455  Millions
Synthorx, Inc.  18.06 $ 150.886  Millions$ 8.357  Millions

Date modified: 2026-09-08T15:09:42+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.